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PMC8 OBJECTIVES: In 2002, the three Local Health Authorities
(LHA’s)of Bologna province (Emilia-Romagna region, Italy)
began an outreach visits program aimed at modifying NHS pre-
scriptions of speciﬁc drugs through evidence-based information
packages and prescribing feedback. Aim of this study is to eval-
uate the impact of the pharmacist’s outreach visits program com-
paring Coxib prescribing volumes between the intervention and
three control LHA’s of the same region (Parma, Ferrara, Imola).
METHODS: Prescribing databases were available for both inter-
vention and control LHA’s from october 2000 to october 2003;
time series data of Coxib monthly consumption were expressed
in DDD’s. For each LHA, 2 time series were considered: the ﬁrst,
based on observed data, plots the real DDD’s trend over 36
months; the second, expected, ﬁts the time series until the inter-
vention date—november 2002—and subsequently forecasts the
forthcoming 12 months estimating DDDs under the hypothesis
of no intervention. Data analysis was performed using SAS/ETS
module(Estimating Time Series) of SAS System: expected time
series were computed with ARIMA intervention modelling.
RESULTS: Since november 2002, all monthly DDD’s observed
in the intervention LHA’s lie under the lower 95% conﬁdence
interval of the estimated DDD’s forecasted by the model; vice
versa, since November 2002, all montly DDD’s observed in the
control LHA’s lie within the 95% conﬁdence interval of the fore-
casted data; this results show a signiﬁcant reduction in prescrib-
ing volumes for the intervention LHA’s. CONCLUSIONS: Use
of ARIMA intervention modelling for drug prescriptions time
series may be a useful and easy to understand way of assessing
the impact of drug information programs in terms of prescrib-
ing modiﬁcations.
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ASP PLUS SIX PERCENT IN 2005-A CONCEPTUAL VIEW OF
FUTURE PHYSICIAN PAYMENTS FOR DRUGS AND THEIR
ADMINISTRATION IN THE OFFICE SETTING
Baker JJ
Resource Group, Ltd, Pickton,TX, USA
OBJECTIVES: In 2005, the Medicare Prescription Drug,
Improvement and Modernization Act (MMA) of 2003 requires
payment for drugs administered in the physician’s ofﬁce at a new
rate of average sales price plus 6%. This study provides a con-
ceptual view of the change and suggests a conceptual modiﬁca-
tion. METHODS: When the MMA imposed the new drug
payment method, it also increased payment for drug adminis-
tration. We postulate these relative weights used for the fee
increases are diluted because they are specialty-speciﬁc rather
than speciﬁc to practice type. This dilution defeats the original
purpose of resource-based practice expenses. EVALUATION OF
RESULTS: Resource-based methods for 2005 related to drugs
and their administration were collected and deconstructed. Leg-
islative rationales for the new drug payment method and for the
differential in transitional procedure payments (32% add-on in
2005 versus 3% add-on in 2006) were identiﬁed. Computations
utilizing the new methods were evaluated for indications of
resource-based level of effort applications. CONCLUSIONS:
Because the drug payment method is new and untested, we esti-
mate a 2-year implementation period is needed before evalua-
tions can occur. We also believe the present formula for indirect
cost allocation within a specialty does not sufﬁciently distinguish
between a practice that provides these high-technology drugs
(high resource consumption) versus other practices that do not
(lower resource consumption). We propose a new add-on com-
ponent within the practice expense formula. This new compo-
nent provides the practice that administers high-technology
drugs with a higher indirect cost weight than a practice that does
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not. Thus the higher resource consumption within the same spe-
cialty is recognized by a weighting factor incorporated into 
the existing practice expense formula. This adjustment to 
the payment formula would achieve equitable recognition of
resource consumption and assist in ensuring access to proper
care by beneﬁciaries.
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COMPARING DIFFERENT APPROXIMATION METHODS FOR
REMAINING LIFE EXPECTANCY IN DECISION TREES
Siebert U, Conrads-Frank A
Harvard Medical School, Boston, MA, USA
OBJECTIVES: Remaining life expectancy (RLE) and quality-
adjusted life expectancy (QALE) are standard outcomes of deci-
sion-analytic Markov models, but their evaluation in decision
trees is less straightforward. We compared Gompertz approxi-
mation (GPA) and Declining Exponential Approximation of Life
Expectancy (DEALE), using life table method as gold standard.
METHODS: All analyses were performed for additive and mul-
tiplicative models for disease-speciﬁc mortality rates (DSM).
Background mortality was estimated from statistical life table
data. In our base case analysis, we set the mortality rate differ-
ence in the additive model being twice the background mortal-
ity at age 45. We set the relative mortality rate ratio to three in
the multiplicative model. We used 1) the formulas by Pollard
based on the Gompertz function, and 2) the DEALE formulas to
calculate undiscounted and discounted RLE and QALE (3%
annual discount rate). Results were compared to actuarial life
table analysis. Bias was deﬁned as percent deviation from the
sum of RLE for ages 30–89. DSM and discount rates were varied
in one-way sensitivity analysis. RESULTS: Both approximation
methods underestimated undiscounted RLE for both, the addi-
tive and multiplicative model. Base case results for men: for the
multiplicative model, GPA (bias -4%) performed better than
DEALE (-49%), whereas for the additive model, DEALE (-6%)
was superior to GPA (-25%). Results for women showed similar
patterns regarding magnitude and direction of bias. The use of
time-independent disease-speciﬁc utility decrements yielded
similar patterns for QALE. When varying DSM in sensitivity
analysis, bias was positively correlated with DSM, but bias direc-
tion (sign) and ranking of both methods did not change. Simi-
larly, changing discount rates did not alter the bias pattern.
CONCLUSIONS: Based on our simulations, the Gompertz func-
tion should be preferred for multiplicative models and the
DEALE approach for additive models. The magnitude of the bias
depends strongly on model parameters.
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EVALUATING DRUG SAFETY USING STOCHASTIC
SIMULATION MODELS
Maguire A1,Arellano FM2, Perez-Gutthan S1
1Pﬁzer, Sant Cugat, Barcelona, Spain; 2Risk Management Resources,
Califon, NJ, USA
OBJECTIVES: To introduce the application of stochastic simu-
lation models in drug safety and demonstrate how the popula-
tion impact of a drug’s safety proﬁle, and other “what if”
scenarios, can be quantiﬁed. METHODS: The patient group is
deﬁned according to the epidemiology of the condition. This
group will form the cohort that will be followed up over a spec-
iﬁed period. Baseline risks of the events and death, in the absence
of drug exposure, are then assigned to each patient according to
age, sex and other relevant risk factors. These parameters are
obtained from available studies. Random times to each event and
death are generated for each patient by applying a model derived
from the exponential distribution; the unique parameter is the
risk of each event. Case fatality is randomly assigned. Following
a non-fatal event during the simulated follow-up, the risk of
recurrent and related events is updated. This cohort provides the
expected number of events and forms a comparator cohort. Sub-
sequently, scenarios of drug exposure, or channeling associated
with drug use, are created and compared with the comparator
cohort. RESULTS: Drug exposure scenarios are modeled by
applying relative risks “RR” to each patient’s baseline risks. The
RRs associated with drug exposure may be sought from studies
or may represent “what if” scenarios. Channeling can be
modeled by altering the composition of the patient group.
Tabular and graphical summaries of the net effect of drug expo-
sure can then be created. CONCLUSIONS: This approach incor-
porates relevant epidemiological data into a single framework,
offers the opportunity of evaluating potential drug safety issues
and may be applied to other aspects of drug risk-beneﬁt.
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DEVELOPING THE EUROPEAN NETWORK OF HEALTH
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THE ACTIVITIES OF ONE CENTRE TO FULFILL BOTH
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Redekop WK1,Van Nooten F1, Bouwmans C1, Rutten F2,
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OBJECTIVES: EURONHEED is an EC-ﬁnanced project to
develop a European Network on Health Economic Evaluation
Databases (2003–2005). The EURONHEED database will
consist of bibliographic records of all published articles regard-
ing health services evaluation for the countries covered by the
network. It will also contain structured abstracts (including crit-
ical commentaries) of all publications describing full economic
evaluations (mainly cost-effectiveness studies). This database will
be publicly accessible via the internet at no charge. This network
presently consists of seven academic centres throughout Europe.
We describe the activities of one centre (Netherlands) in the
context of this initiative. METHODS: Each EURONHEED
centre will develop and maintain a local database covering one
region. To ensure that individual databases can be combined 
to create a larger “meta-database”, all centres will use a general
methodology and database structure. The approach used is based
on two existing databases: CODECS (Collège des Economistes
de la Santé (CES), Paris) and NHS EED (Centre for Reviews and
Dissemination, York, UK). RESULTS: Both have been opera-
tional for years and are already accessible. The EURONHEED
group has developed a common strategy for the management and
maintenance of the databases. To “localise” this strategy, we
have developed a 10-step system, from literature searching to
publicly accessible abstracts. This system also includes internal
quality assurance and recordkeeping. We have also contacted 27
institutions in The Netherlands and Flanders and requested lists
of all recent publications. This will help to ensure the identiﬁca-
tion of all relevant publications regarding health services evalu-
ation in The Netherlands. CONCLUSIONS: Both our local
database and the whole EURONHEED database will soon be
accessible (Dec 2004) for both local and European users. Local
decision-making will be supported by easy identiﬁcation of all
Dutch publications. Moreover, use of a common methodology
and database structure will allow searches of the entire EURON-
HEED database.
